Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a specialty pharmaceutical company focused on innovative drug discovery and global commercialization. It serves industries related to oncology, nephrology, the central nervous system, and immunology. Its global business also focuses on bone and mineral, intractable hematological diseases/hemato oncology, and rare diseases. The company also collaborates with research partners worldwide to ensure the delivery of novel medicines to patients.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Kyowa Kirin is actively investing in research and development (R&D) activities to advance its technological and disease pillars. The company focuses on establishing innovative drugs for diseases with unmet medical needs, utilizing its proprietary antibody technologies and diverse drug discovery technologies. The company is also engaged in developing next-generation therapeutic antibodies and hematopoietic stem cell gene therapy, aiming to provide life-changing value through new drugs. Additionally, Kyowa Kirin emphasizes open innovation and strategic collaborations to enhance its R&D efforts. The disease science areas on which the company's R&D focuses are bone and mineral, blood cancer, intractable blood diseases, and rare diseases. In terms of drug discovery technology, the company aims to continuously create new drugs by strengthening innovative modalities such as advanced antibody technology and hematopoietic stem cell gene therapy. Kyowa Kirin also conducts open innovation activities, promotes collaboration with partners, invests in venture capital funds, and corporate venture capital. The R&D units of Kyowa Kirin include the Tokyo Research Park, Fuji Research Park, Bio Process Research and Development Laboratories, and the CMC R&D Center. In FY2025, the company spent JPY101,183 million on its R&D activities, which as a percentage of revenue, stood at 20.4%.